BPC-157 (Body Protection Compound 157) has become one of the most extensively studied synthetic peptides in preclinical research, with over 100 peer-reviewed studies examining its biological activity across multiple physiological systems. For Australian researchers sourcing reference-grade peptides, understanding the science behind BPC-157 is essential context for experimental design and compound selection.
This article provides a structured overview of BPC-157’s molecular identity, proposed mechanisms, and the current state of preclinical research — for laboratory reference purposes only.
What Is BPC-157?
BPC-157 is a synthetic pentadecapeptide composed of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), structurally derived from a protective gastric protein sequence identified in human gastric juice. It is classified as a research compound with no current clinical approval in any jurisdiction. All published research on BPC-157 has been conducted in vitro or in animal models.
Its stability distinguishes it from many other research peptides: BPC-157 retains activity across a wide pH range and shows resistance to enzymatic degradation under gastric conditions, making it a robust tool for controlled experimentation.
Molecular Identity
- Full name: Body Protection Compound 157
- Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Chain length: 15 amino acids
- CAS number: 137525-51-0
- Molecular formula: C₅₂H₉₈N₁₆O₂₂
- Molecular weight: 1419.55 g/mol
Proposed Mechanisms of Action
1. VEGFR2 Activation and Angiogenesis
One of the most cited proposed mechanisms of BPC-157 is upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), which is associated with endothelial cell migration and new blood vessel formation. Pro-angiogenic effects have been consistently observed in preclinical wound-healing models. A 2025 review in Pharmaceuticals noted BPC-157’s modulatory effects on vasomotor tone and endothelial nitric oxide synthase (eNOS) pathway activation.
2. Nitric Oxide Pathway Modulation
Animal studies have suggested that BPC-157 interacts with the nitric oxide (NO) system through a dual mechanism — attenuating cytotoxic and damaging effects of excessive NO while preserving its essential protective vascular functions. This nuanced interaction with the NO pathway has been a focus of ongoing scientific debate regarding interpretation of precise mechanisms and whether findings can be generalised beyond the primary research centre.
3. Collagen Synthesis and Tendon Repair
A 2025 systematic review published in the Orthopaedic Journal of Sports Medicine evaluated 36 studies on BPC-157 in musculoskeletal research (35 preclinical, 1 clinical). The review found that BPC-157 enhanced growth hormone receptor expression and activated pathways associated with cell growth, collagen organisation, and fibroblast migration. Authors noted increased collagen deposition and tendon-to-bone remodelling markers in animal ligament and tendon injury models.
4. Gastrointestinal Mucosal Research
BPC-157 was originally derived from gastric protein sequences, and much of the early research examined its effects on GI mucosal integrity. Animal studies have explored its activity in models of gastric ulceration, inflammatory bowel conditions, and intestinal anastomosis healing, observing modulation of cytokine profiles and mucosal barrier markers.
5. Dopaminergic and Neurochemical Models
More recent animal studies have begun examining BPC-157’s interactions with dopaminergic and serotonergic pathways, including effects on dopamine receptor expression and behaviours in rat models of stress and neurological challenge. This remains an early and expanding area of preclinical investigation.
State of the Research
The majority of BPC-157 publications — approximately 80% of records on Google Scholar and PubMed — have originated from a single research centre (University of Zagreb, led by Professor Predrag Sikirić). While this body of work is substantial and internally consistent, the scientific community has called for independent replication from multiple institutions. A 2025 exchange in Pharmaceuticals highlighted both the strengths of the existing dataset and ongoing methodological debates around nitric oxide mechanism interpretation.
As of 2026, no Phase I clinical trials of BPC-157 have been completed in a regulatory framework. It remains a preclinical-stage research compound.
BPC-157 vs TB-500: Key Differences for Researchers
These two peptides are frequently studied in combination but have distinct profiles. BPC-157 is a 15-amino-acid synthetic sequence with primary research interest in GI protection, tendon repair, and vascular signalling. TB-500 (a fragment of Thymosin Beta-4) is a 43-amino-acid peptide with research interest in actin regulation, cellular migration, and tissue repair at a broader systems level. Animal models of musculoskeletal injury have examined both compounds individually and in combination.
Browse BPC-157 and TB-500 research compounds →
Storage and Handling (Research Reference)
Lyophilised BPC-157 should be stored at −20°C in a dry, dark environment. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 4 weeks. Avoid repeated freeze–thaw cycles by aliquoting before freezing. See our complete peptide storage guide for full protocols.
Sourcing BPC-157 for Research in Australia
For Australian researchers, sourcing quality matters as much as the compound itself. Third-party COA verification (HPLC purity + mass spectrometry identity confirmation) is the minimum standard for legitimate research material. All BPC-157 supplied by PureRawz Australia is independently tested at ≥99% purity with a batch-specific Certificate of Analysis.
View BPC-157 research compounds →
Frequently Asked Questions
What is BPC-157 used for in research?
BPC-157 is studied in preclinical models for its effects on angiogenesis, collagen synthesis, tendon and musculoskeletal tissue repair, gastrointestinal mucosal integrity, and neurochemical pathways. All published research is conducted in vitro or in animal models; no clinical approvals exist.
Is BPC-157 legal in Australia?
BPC-157 is not a scheduled substance under the TGA Poisons Standard and is legally available in Australia for laboratory and research use only. It is not approved for human therapeutic use and must not be used for human or veterinary consumption.
What purity should BPC-157 be for research purposes?
Research-grade BPC-157 should be a minimum of 95% purity (HPLC-verified), with premium research material at ≥99%. Always request a batch-specific COA with HPLC chromatogram from your supplier to verify both purity and molecular identity by mass spectrometry.
How does BPC-157 differ from TB-500 in research models?
BPC-157 is a 15-amino-acid synthetic gastric peptide primarily studied for GI, tendon, and vascular signalling effects. TB-500 (Thymosin Beta-4 fragment) is a 43-amino-acid peptide researched for actin regulation and broader cellular migration activity. The two are often studied in combination in animal models of musculoskeletal injury and are considered complementary rather than duplicative.
How should BPC-157 be stored in a research setting?
Lyophilised BPC-157: store at −20°C, protected from light and moisture, for up to 24 months. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 4 weeks. Do not vortex or shake; gently swirl to dissolve. Aliquot before freezing to avoid repeat freeze–thaw cycles.
For laboratory and research use only. Not for human or veterinary consumption. Nothing in this article constitutes medical advice.
